AbbVie Results Reflect Humira Hit In Q3

US Sales Down By Almost Two-Fifths As Adalimumab Biosimilar Competition Bites

 
• By David Wallace
Arrows down (Zoonar GmbH/Alamy Stock Photo)
Humira sales took a hit in Q3 (Zoonar GmbH / Alamy Stock Photo/Alamy Stock Photo)

More from Biosimilars

More from Products